APOA1 and amyotrophic lateral sclerosis: Similar to previous study results, ApoA1 treatment at doses of both 50 μg/ml and 100 μg/ml significantly (p < 0.01) decreased mBEC death (11.25 ± 1.83% and 3.99 ± 0.70%, respectively; Fig. 3C,E,G) versus cell culture supplemented with ALS mouse plasma alone (24.38 ± 3.38%; Fig. 3B,G).